Search

Oxymetazoline hydrochloride for improved symmetry in Graves’ disease

Oxymetazoline hydrochloride 0.1% ophthalmic solution has Food & Drug Administration (FDA) approval for use in involution ptosis. It is an alpha 1 agonist and partial alpha 2 agonist that stimulates Muller’s muscle to lift the lid. The authors of this...

Short-term instability of surgical correction of IXT

In this retrospective observation study from southern India, the authors aimed to evaluate the progression of intermittent exotropia (IXT) following surgical correction and its contributing factors in 50 patients. Mean age at surgery was 10 years (range 6–14), 26 were...

Understanding the pachychoroid disease spectrum

This article provides a comprehensive review of the pachychoroid disease spectrum, a group of chorioretinal disorders characterised by abnormal choroidal thickening and various pathological changes in the choroid, retinal pigment epithelium, and retina. It also highlights the controversies and knowledge...

Retinal thickness and visual acuity change correlations after amblyopia occlusion therapy

This prospective study aimed to assess change in retinal nerve fibre layer (RNFL) and macular thickness, and clinical correlations with visual outcomes, after amblyopia treatment in 30 children with moderate to severe amblyopia. Mean age of children was 5.26 ±1.65...